Omeros OMER
NASDAQ OMER
$18.95 -0.16 (-0.84%)
At close: Sep 4, 2026 · 4:00 PM EDT

Omeros (OMER) Cash from Financing Activities (2010 - 2026)

Omeros (OMER) posted Cash from Financing Activities of -$22.0 million for Q1 2026, up 65.89% sequentially from -$64.4 million in Q4 2025, and down 1095.32% YoY from $2.2 million in Q1 2025.

Analysis

Omeros (OMER) Cash from Financing Activities (2010 - 2026) Analysis & Trends

Omeros has reported Cash from Financing Activities for 17 years, with the latest figure at -$22.0 million in Q1 2026.

  • Quarterly Cash from Financing Activities fell 1095.32% year-over-year to -$22.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$62.3 million (down 66.66% YoY) and the FY2025 annual result came in at -$42.2 million, down 167.06% from the prior year.
  • Cash from Financing Activities advanced to -$22.0 million in Q1 2026 per OMER's latest filing, from -$64.4 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $124.8 million in Q3 2022 and troughed at -$105.0 million in Q4 2023.
  • A 5-year average of $993764.7 and a median of -$651000.0 in 2022 frame the typical range for Cash from Financing Activities.
  • The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities soared 26016.53% in 2022, then slumped 16021.81% in 2023.
  • Over 5 years, Cash from Financing Activities stood at -$651000.0 in 2022, then plunged by 16021.81% to -$105.0 million in 2023, then soared by 96.1% to -$4.1 million in 2024, then tumbled by 1473.6% to -$64.4 million in 2025, then soared by 65.89% to -$22.0 million in 2026.
  • According to Business Quant data, Cash from Financing Activities over the past three periods registered -$22.0 million, -$64.4 million, and $25.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -426.70 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -1.22 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 14.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 2.42 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -6.05 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 36.24 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -273.15 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 27.18 Mn
10 Omeros 1.38 Bn 1.38 Bn 27.73 Mn -7.47 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -7.47 Mn
Mar 31, 2026 -21.98 Mn
Dec 31, 2025 -64.44 Mn
Sep 30, 2025 25.83 Mn
Jun 30, 2025 -1.72 Mn
Mar 31, 2025 -1.84 Mn
Dec 31, 2024 -4.10 Mn
Sep 30, 2024 -4.58 Mn
Jun 30, 2024 -26.88 Mn
Mar 31, 2024 98.43 Mn
Dec 31, 2023 -104.95 Mn
Sep 30, 2023 -483,000.00
Jun 30, 2023 -260,000.00
Mar 31, 2023 -388,000.00
Dec 31, 2022 -651,000.00
Sep 30, 2022 124.84 Mn
Jun 30, 2022 -99,000.00
Mar 31, 2022 161,000.00
Dec 31, 2021 -810,000.00
Sep 30, 2021 478,000.00